NCT02275299View on ClinicalTrials.gov

Study of Iguratimod Plus Methotrexate Compared to Leflunomid Plus Methotrexate in Patients With Rheumatoid Arthritis

PHASE4UnknownINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Iguratimod

Iguratimod 25 mg/tablet, taken orally, 2 tablets/day (bid),52 weeks

DRUG

Leflunomide

Leflunomide 10 mg/tablet, taken orally, 2 tablets/day (bid),52 weeks

DRUG

Methotrexate

Methotrexate 2.5 mg/tablet, taken orally once a week, 4 tablets/week,52 weeks

Trial Locations (1)

100032

RECRUITING

Peking Union Medical College Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Jiangsu Simcere Pharmaceutical Co., Ltd.

INDUSTRY